Press Release Details

View all news


July 13, 2009

HERCULES, CA and BILLERICA, MA – July 13, 2009 Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of the Lucid ™ ID Access Pack, the first product designed for the Lucid Proteomics System ™ , a proteomics solution in development by Bio‑Rad and Bruker Corporation (NASDAQ: BRKR) that will combine Bio-Rad's ProteinChip ® surface-enhanced laser desorption/ionization (SELDI)-based array technology with Bruker's ultrafleXtreme MALDI-TOF/TOF mass spectrometer, enabling researchers to use both top-down and bottom-up proteomics approaches for biomarker discovery on the same system. With the Lucid ID Access Pack, researchers who currently profile their biomarkers using Bio‑Rad's ProteinChip ® array technology can use the Lucid ID Access Pack to complete the biomarker purification process and identify these biomarkers with high confidence.

A distinct advantage of the Lucid ID Access Pack is the ability to identify peptides under 4 kilodaltons directly on a ProteinChip array after a simple, one-step enrichment. Identification of proteins and peptides over 4 kilodaltons that require trypsin digestion is demystified by following Bio‑Rad's Biomarker Purification and Identification Guide and by using ProteinChip arrays in conjunction with Bruker's ultrafleXtreme MALDI-TOF/TOF, which has been optimized for the ability to read ProteinChip arrays. This new high-performance system delivers the resolution required for rapid, high-confidence protein identification. For convenience, the Lucid ID Access Pack is also backwards-compatible with other Bruker autofleX and ultrafleX MALDI TOF/TOF systems.

The Lucid ID Access Pack contains the essential accessories and consumables needed for high-confidence identification of putative biomarkers, including:

•  A chip holder specifically designed to analyze ProteinChip arrays on the Lucid Proteomics System

•  ProteinChip arrays with chromatographic surfaces most commonly used in identification protocols

•  A manual including optimized instrument settings for on-chip peptide identification

•  All necessary user licenses

•  Personalized consulting with premier experts on purification and enrichment strategies

About the Lucid Proteomics System

The Lucid Proteomics System combines and refines surface-enhanced laser desorption/ionization (SELDI) from Bio-Rad and time-of-flight (TOF/TOF) technologies from Bruker, enabling both top-down and bottom-up proteomics approaches for biomarker discovery on one system. The system offers new solutions for protein biomarker discovery, in particular, high-throughput profiling and high-confidence identification of intact peptides and proteins under 30 kilodalton, which are challenging for current technologies to identify. For more information, visit

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit  

Bio-Rad Introduces the Lucid ID Access Pack

About Bruker Daltonics

Bruker Daltonics is a leading manufacturer of mass spectrometry (MS) instruments and accessories for life science, pharmaceutical, biochemical and chemical research as well as for applied analytical tasks in forensics and food safety. Technical solutions are based on a comprehensive range of MALDI-TOF/TOF, ESI-Qq-TOF, ESI-ITMS, and ESI/MALDI-FTMS mass spectrometry systems, as well as automated sample handling systems and productivity enhancing software. For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit and

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form

8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:

Julie Hey
Bio-Rad Laboratories, Inc.

Ken Li
Chempetitive Group
312-997-2436 x112

Darwin Asa
Bruker Daltonics, Inc.
978-663-3660 x1149

Categories: Press Releases
View all news